WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H576364
CAS#: 118909-22-1
Description: Velnacrine maleate is an hydroxylated derivative of the acetylcholinesterase inhibitor tacrine.
Hodoodo Cat#: H576364
Name: Velnacrine maleate
CAS#: 118909-22-1
Chemical Formula: C17H18N2O5
Exact Mass: 330.12
Molecular Weight: 330.340
Elemental Analysis: C, 61.81; H, 5.49; N, 8.48; O, 24.22
Synonym: HP 029 maleate; HP029 maleate; HP-029 maleate; Mentane; P83 6029A; Velnacrine maleate
IUPAC/Chemical Name: 1-Acridinol, 9-amino-1,2,3,4-tetrahydro-, (+-)-, (Z)-2-butenedioate (1:1) (salt)
InChi Key: NEEKVKZFYBQFGT-BTJKTKAUSA-N
InChi Code: InChI=1S/C13H14N2O.C4H4O4/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13;5-3(6)1-2-4(7)8/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15);1-2H,(H,5,6)(H,7,8)/b;2-1-
SMILES Code: Nc1c2C(O)CCCc2nc3ccccc13.OC(=O)\C=C/C(=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 330.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Birks J, Wilcock GG. Velnacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2004;(2):CD004748. doi: 10.1002/14651858.CD004748. PMID: 15106259.
2. Sahoo AK, Dandapat J, Dash UC, Kanhar S. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. J Ethnopharmacol. 2018 Apr 6;215:42-73. doi: 10.1016/j.jep.2017.12.015. Epub 2017 Dec 14. PMID: 29248451.
3. Dembitsky VM, Dzhemileva L, Gloriozova T, D'yakonov V. Natural and synthetic drugs used for the treatment of the dementia. Biochem Biophys Res Commun. 2020 Apr 9;524(3):772-783. doi: 10.1016/j.bbrc.2020.01.123. Epub 2020 Feb 7. PMID: 32037088.
4. Goa KL, Fitton A. Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential. CNS Drugs. 1994 Mar;1(3):232-40. doi: 10.2165/00023210-199401030-00008. PMID: 27520522.